drugset / Trial / NCT04160416
mXELOXIRI Combined With Molecular Targeted Drug in mCRC
NaSingle-groupOpen-labelTreatment
Summary
The objective is to evaluate the efficacy and safety of modified XELOXIRI combined with molecular targeted drug as first-line therapy in patients with metastatic colorectal cancer (mCRC)
Timeline
- Start
- 2019-07-01
- Primary completion
- 2020-11-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1600 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 68 mg/m2 | Intravenous |